Donna Grogan
Director/Board Member presso C4 THERAPEUTICS, INC.
Patrimonio netto: 193 073 $ in data 31/03/2024
Profilo
Donna Roy Grogan is an Independent Director at C4 Therapeutics, Inc. since 2022 and the President at Clementia Pharmaceuticals USA, Inc. since 2014.
She previously served as an Independent Director at Momenta Pharmaceuticals, Inc. from 2019 to 2020.
Donna also held positions as the Chief Medical Officer at DecImmune Therapeutics, Inc., Apofore Corp., and Anexon, Inc. She was the Senior Vice President-Clinical Research at Sumitomo Pharma America, Inc. from 2000 to 2007 and the Chief Medical Officer at Clementia Pharmaceuticals, Inc. from 2013 to 2019.
Additionally, she served as the Chief Medical Officer at FoldRx.
Pharmaceuticals LLC from 2007 to 2011.
Donna's education includes an undergraduate degree from the College of the Holy Cross (Massachusetts) and a doctorate from the University of Illinois College of Medicine.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
C4 THERAPEUTICS, INC.
0.03% | 01/04/2024 | 23 632 ( 0.03% ) | 193 073 $ | 31/03/2024 |
Posizioni attive di Donna Grogan
Società | Posizione | Inizio |
---|---|---|
C4 THERAPEUTICS, INC. | Director/Board Member | 29/07/2022 |
Clementia Pharmaceuticals USA, Inc.
Clementia Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Part of Ipsen SA, Clementia Pharmaceuticals USA, Inc. is a biopharmaceutical company that aims to improve health outcomes and create a positive impact for patients and society. The private company is based in Newton, MA and focuses on developing innovative medicines in oncology, neuroscience, and rare diseases. Ipsen, the parent company, regularly plans and conducts informative and transparent events for the investor community. | President | 01/06/2014 |
Precedenti posizioni note di Donna Grogan
Società | Posizione | Fine |
---|---|---|
MOMENTA PHARMACEUTICALS, INC. | Director/Board Member | 01/10/2020 |
CLEMENTIA PHARMACEUTICALS INC | Chief Tech/Sci/R&D Officer | 01/04/2019 |
FoldRx Pharmaceuticals LLC
FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01/08/2011 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Corporate Officer/Principal | 01/01/2007 |
DecImmune Therapeutics, Inc.
DecImmune Therapeutics, Inc. BiotechnologyHealth Technology DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute and tissue damaging inflammation. It engages in developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway. The company was founded by Michael Carroll, Richard S. Foemmel, and Francis Moore Jr. on March 27, 2001 and is headquartered in Cambridge, MA.^ | Chief Tech/Sci/R&D Officer | - |
Formazione di Donna Grogan
College of the Holy Cross (Massachusetts) | Undergraduate Degree |
University of Illinois College of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
C4 THERAPEUTICS, INC. | Health Technology |
Aziende private | 9 |
---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
FoldRx Pharmaceuticals LLC
FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA. | Health Technology |
DecImmune Therapeutics, Inc.
DecImmune Therapeutics, Inc. BiotechnologyHealth Technology DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute and tissue damaging inflammation. It engages in developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway. The company was founded by Michael Carroll, Richard S. Foemmel, and Francis Moore Jr. on March 27, 2001 and is headquartered in Cambridge, MA.^ | Health Technology |
Apofore Corp.
Apofore Corp. Pharmaceuticals: MajorHealth Technology Apofore Corp. developed novel therapeutics for diabetes. The company was headquartered in Cambridge, MA. | Health Technology |
Astra Pharmaceuticals, Inc. | |
Anexon, Inc.
Anexon, Inc. Pharmaceuticals: MajorHealth Technology Anexon, Inc. develops therapeutics for cardiovascular diseases. The firm develops an alternatively spliced variant of brain natriuretic peptide, ANX-042, for the treatment of patients with chronic heart failure and kidney dysfunction. The company was founded in 2006 by Robert D. Simari and is headquartered in Cambridge, MA. | Health Technology |
Clementia Pharmaceuticals, Inc.
Clementia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Clementia Pharmaceuticals, Inc. provides healthcare services. It is a biopharmaceutical company, which focuses on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease and involves in development and commercialization of treatments for people living with rare diseases. Clementia Pharmaceuticals was founded by Clarissa Desjardins and Jean-Claude Tardif on November 5, 2010 and is headquartered in Montreal, Canada. | Health Technology |
Clementia Pharmaceuticals USA, Inc.
Clementia Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Part of Ipsen SA, Clementia Pharmaceuticals USA, Inc. is a biopharmaceutical company that aims to improve health outcomes and create a positive impact for patients and society. The private company is based in Newton, MA and focuses on developing innovative medicines in oncology, neuroscience, and rare diseases. Ipsen, the parent company, regularly plans and conducts informative and transparent events for the investor community. | Health Technology |
- Borsa valori
- Insiders
- Donna Grogan